QIAGEN získal od FDA schválení pro QIAstat-Dx BCID GPF Plus AMR Panel, první panel platformy QIAstat-Dx pro diagnostiku krevních infekcí. Test odhalí 20 gram-pozitivních bakteriálních a houbových cílů i široký pan gram-negativní cíl spolu s 10 markery rezistence z pozitivní hemokultury asi za hodinu.
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
The clearance expands QIAGEN’s U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is available in more than 100 countries and with more than 5,200 cumulative placements as of the end of 2025.
The QIAstat-Dx BCID GPF Plus AMR Panel detects 20 gram-positive bacterial and fungal pathogen targets as well as a broad pan gram-negative target together with 10 genetic antimicrobial resistance markers from positive blood culture samples in about one hour. The rapid identification of pathogens and resistance gene markers can support informed treatment decisions, antimicrobial stewardship and infection prevention measures.
Bloodstream infections are associated with significant morbidity and mortality and can rapidly progress to sepsis, a life-threatening reaction to an infection that causes your immune system to harm healthy tissues and organs. An estimated 1.7 million adults in the U.S. develop sepsis each year1, highlighting the importance of providing clinicians with timely diagnostic information.
“Every hour, even minutes, count with bloodstream infections,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “This clearance gives U.S. laboratories a fast and integrated way to identify pathogens and key genetic antimicrobial resistance markers, supporting more informed treatment decisions and responsible antibiotic use. It also establishes the first member of a broader QIAstat-Dx bloodstream infection panel family planned for the U.S.”
The QIAstat-Dx system integrates sample preparation, multiplex PCR testing and data analysis into a single workflow. It is designed to provide rapid and easy-to-interpret results while reducing hands-on time for laboratory professionals.
The FDA clearance also lays the foundation for the continued expansion of QIAGEN’s bloodstream infection testing portfolio in the U.S. A complementary QIAstat-Dx BCID GN Plus AMR Panel, designed to detect gram-negative pathogens and associated genetic antimicrobial resistance markers, is currently under FDA review.
QIAGEN has been consistently expanding the QIAstat-Dx menu for the U.S., broadening the platform across four major infectious disease areas: respiratory, gastrointestinal, central nervous system and now bloodstream infections. The portfolio includes the QIAstat-Dx Respiratory Panel Plus, the QIAstat-Dx Respiratory Panel Mini, the QIAstat-Dx Gastrointestinal Panel 2, the QIAstat-Dx GI Panel 2 Mini B, the QIAstat-Dx GI Panel 2 Mini B&V, the QIAstat-Dx Meningitis/Encephalitis Panel and the newly FDA-cleared QIAstat-Dx BCID GPF Plus AMR Panel. This reflects QIAGEN's strategy of building a comprehensive infectious disease testing menu on a single integrated platform.
For more information about the QIAstat-Dx BCID GPF Plus AMR Panel and the QIAstat-Dx system, visit www.qiagen.com/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to QIAGEN's filings with the U.S. Securities and Exchange Commission.
1 Centers for Disease Control and Prevention (CDC). About Sepsis. Available at: https://www.cdc.gov/sepsis/about/index.html (accessed August 2026).
Qiagen oznámil za 2. čtvrtletí tržby 535 mil. USD a upravený zředěný EPS 0,62 USD, oba nad výhledem. Firma potvrdila celoroční výhled růstu tržeb 1 % až 2 %.
Strategic Buy Lights Up This Biotech Stock: Time to Invest?Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings per share were $0.62, exceeding guidance of at least $0.60 at constant exchange rates.
Chief Executive Officer Thierry Bernard said the company’s growth pillars rose 5% at constant exchange rates during the quarter, led by Sample Technologies, QIAcuity digital PCR and QIAGEN Digital Insights. He said QuantiFERON latent tuberculosis testing returned to growth despite a significant decline in U.S. immigration testing demand, while QIAstat-Dx faced a difficult comparison in respiratory testing.
Get Qiagen alerts:
Product-group performance varied Sample Technologies sales increased 9% at constant exchange rates, supported by automated consumables and higher instrument sales compared with the prior-year period. Diagnostic Solutions revenue declined 2% at constant exchange rates. Within that segment, QuantiFERON grew 1%, as demand across most testing groups outweighed lower immigration testing demand in the U.S. and Middle East.
QIAstat-Dx sales fell 7% at constant exchange rates. Growth in gastrointestinal and meningitis panels was offset by lower respiratory-panel sales against a strong prior-year comparison. PCR and nucleic acid amplification sales declined 8%, although QIAcuity delivered double-digit growth driven by consumables demand. The growth in QIAcuity was more than offset by weaker OEM demand, according to Chief Financial Officer Roland Sackers.
Genomics and next-generation sequencing sales rose 2% at constant exchange rates. QIAGEN Digital Insights posted solid single-digit growth, while consumables for universal NGS panels used on third-party sequencers grew more than 20%. Lower sales of other genomics products moderated the segment’s overall growth rate.
Americas sales rose 1% at constant exchange rates, including 2% growth in North America. EMEA sales declined 2%, with gains in Spain, Belgium and Poland offset by declines in Germany, France and Italy. Asia-Pacific sales declined 2%, though the region excluding China grew at a low-single-digit rate and Japan posted high-teens growth. China sales declined in the low teens year over year, but improved sequentially at a double-digit percentage rate. Margins and cash flow remained high Adjusted operating income declined 2% to $157 million, while the adjusted operating margin was 29.4%, compared with 29.9% in the second quarter of 2025. Sackers said disciplined cost management and efficiency measures helped offset product-mix-related pressure on gross margin. The adjusted cost margin was 66.2%, down from 66.7% a year earlier.
The operating margin improved by 200 basis points sequentially from 27.4% in the first quarter. Qiagen’s adjusted tax rate was 18%, within its 17% to 18% target range.
Operating cash flow totaled $301 million for the first six months of 2026, unchanged from the same period in 2025. The figure included approximately $20 million in cash payments tied to efficiency and restructuring programs, as well as a planned inventory increase ahead of product launches. Days sales outstanding improved to approximately 55 days from 57 days at the end of 2025, while days inventory outstanding increased to 153 from 149.
The company completed a $500 million synthetic share repurchase in January and paid an approximately $72 million annual dividend in July. The dividend rose 40% to $0.35 per share from $0.25 in 2025.
New launches underpin second-half expectations Bernard highlighted progress in the company’s automation portfolio, including the commercial launch of QIAsymphony Connect and early placements of QIAsprint Connect. QIAmini remains scheduled for a fall launch, with beta field testing in North America expected to begin in coming weeks.
In diagnostics, Qiagen launched two QIAstat-Dx bloodstream infection panels in Europe that collectively detect 33 pathogens and 28 antimicrobial resistance markers in about one hour. Bernard said the company expects FDA approval for the panels by year-end. Qiagen also expects its complicated urinary tract infection panel to be available in Europe during the second half of 2027.
The company plans to launch new QIAcuity gene-expression assays and a multiplex kit for up to 12 RNA targets in a single reaction during the second half of 2026. It is also working with DiaSorin and Inpeco on a fully automated QuantiFERON Sample to Insight workflow, targeted for launch in the second half of 2027.
Guidance reaffirmed; strategic review continues Qiagen reaffirmed its full-year outlook for constant-exchange-rate sales growth of about 1% to 2% and adjusted diluted EPS of at least $2.43. For the third quarter, the company forecast sales growth of approximately 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $0.62.
Sackers said the company expects sales growth to improve from a 1% decline in the first half to roughly 3% to 4% in the second half. Management cited the end of headwinds from discontinued NeuMoDx and bioinformatics portfolios, contributions from recent product launches, Parse single-cell analysis performance ahead of its approximately $40 million 2026 sales target, and modestly improving U.S. life-science funding conditions.
Bernard said Qiagen’s CEO search and strategic review are complementary but independent processes. He reiterated that the CEO transition is expected during the second half of 2026 and said the company will continue evaluating options intended to increase shareholder and stakeholder value.
About Qiagen (NYSE:QGEN)Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Qiagen Right Now?Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Qiagen ve 2. čtvrtletí zvýšil tržby na 535,04 mil. USD, nad odhady, a EPS činil 0,62 USD. Klíčové bylo i silné překonání u Sample Technologies: 182 mil. USD, +9,6 % meziročně.
For the quarter ended June 2026, Qiagen (QGEN - Free Report) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $527.94 million, representing a surprise of +1.35%. The company delivered an EPS surprise of +3.33%, with the consensus EPS estimate being $0.60.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Qiagen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Sales by Product Groups- Diagnostic solutions- QIAstat-Dx: $32 million versus the four-analyst average estimate of $36.58 million. The reported number represents a year-over-year change of -5.9%.Sales by Product Groups- Diagnostic solutions- QuantiFERON: $131 million versus $127.81 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.6% change.Sales by Product Groups- Diagnostic solutions- Other: $40 million versus the three-analyst average estimate of $29.5 million. The reported number represents a year-over-year change of 0%.Sales by Product Groups- Other: $15 million versus $14.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change.Sales by Product Groups- PCR / Nucleic acid amplification: $74 million versus $69.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.Sales by Product Groups- Genomics / NGS: $61 million versus $59.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.4% change.Sales by Product Groups- Diagnostic solutions: $204 million versus the three-analyst average estimate of $202.46 million. The reported number represents a year-over-year change of -1%.Sales by Product Groups- Sample technologies: $182 million compared to the $181.19 million average estimate based on three analysts. The reported number represents a change of +9.6% year over year.View all Key Company Metrics for Qiagen here>>>
Shares of Qiagen have returned +9.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis cases reported across the United States.
More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May, along with another 7,000 potential cases, as health authorities investigate multiple outbreaks involving Cyclospora cayetanensis, a foodborne parasite that can cause prolonged diarrhea and other gastrointestinal symptoms. The parasite is not detected through routine stool culture and requires specialized diagnostic methods, including molecular testing.
QIAGEN's Sample to Insight portfolio supports laboratories across the molecular testing continuum, from syndromic diagnostics and digital PCR to next-generation sequencing (NGS):
The FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as a standard target within its 16-target menu for bacterial, viral and parasitic pathogens. The fully integrated syndromic test delivers results in about an hour, enabling laboratories to test for Cyclospora alongside other common causes of gastrointestinal illness from the initial patient sample. For research use only, QIAGEN offers the digital PCR Microbial DNA Detection Assay targeting Cyclospora cayetanensis for use with the QIAcuity digital PCR system, supporting highly sensitive detection in research and public health applications. QIAGEN's sequencing portfolio also includes the PulseNet-approved QIAseq FX DNA Library Prep Kit for research use only with any NGS sequencer. This kit is designed to support “shotgun sequencing workflows” that analyze all DNA in a sample to help identify and characterize foodborne pathogens for PulseNet, the U.S. public health laboratory network that detects and investigates foodborne disease outbreaks. “The current rise in cyclosporiasis cases highlights the need for rapid, reliable detection to support timely patient care and effective public health action,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “QIAGEN is ready to support laboratories and public health authorities worldwide with molecular testing technologies that help detect infections, guide investigations and strengthen responses to emerging disease threats.”
Further information about QIAGEN's molecular testing solutions supporting clinical diagnostics, research and public health laboratories is available through local QIAGEN representatives or the QIAGEN Customer Care team on www.qiagen.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
QIAGEN v Evropě uvedla panel QIAstat-Dx BCID GN Plus AMR certifikovaný podle CE-IVDR pro rychlou detekci 13 gramnegativních patogenů a 18 markerů AMR z pozitivních hemokultur za přibližně hodinu.
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe.
The new QIAstat-Dx BCID GN Plus AMR Panel detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance (AMR) markers from positive blood cultures in about one hour. It complements the recently launched QIAstat-Dx BCID GPF Plus AMR Panel in Europe, extending QIAGEN's bloodstream infection testing coverage across gram-positive bacteria, gram-negative bacteria, fungi and key AMR markers. Together, the two panels detect 33 pathogen targets and 28 AMR markers, enabling rapid identification of the most clinically relevant bloodstream pathogens and resistance mechanisms to support earlier pathogen identification and clinical decision-making.
“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control.”
Gram-negative pathogens are among the leading causes of bloodstream infections and are frequently associated with AMR, one of the world's most significant public health threats. AMR occurs when bacteria develop mechanisms that render antibiotics ineffective, making infections more difficult to treat and increasing the risk of severe illness and death. In bloodstream infections, delays in identifying resistant pathogens can postpone appropriate therapy, while the growing burden of beta-lactam resistance driven by extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms underscores the need for rapid and accurate detection. With broad coverage of key beta-lactam resistance mechanisms, the QIAstat-Dx BCID GN Plus AMR Panel provides rapid, actionable molecular insights to support optimized treatment decisions and infection control.
The QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified and available in applicable markets. Regulatory review by the U.S. Food and Drug Administration is underway.
QIAGEN's CE-IVDR-certified QIAstat-Dx menu in Europe spans key syndromic testing areas, including respiratory infections, gastrointestinal infections, central nervous system infections through its meningitis / encephalitis panel and bloodstream infection testing. With the addition of the BCID GN Plus AMR Panel, the QIAstat-Dx platform now provides comprehensive bloodstream infection testing through complementary gram-positive and gram-negative panels. Built around rapid, cartridge-based molecular testing, QIAstat-Dx integrates sample preparation, molecular analysis and result interpretation into a streamlined workflow, helping laboratories generate clinically relevant insights across a growing range of infectious disease applications.
QIAstat-Dx systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.
For more information about the QIAstat-Dx BCID GN Plus AMR Panel and the QIAstat-Dx system, visit https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
